
Paige is an AI-powered digital pathology company developing artificial intelligence applications for cancer detection and diagnosis. The company leverages proprietary deep learning models and one of the world's largest clinically annotated datasets of digitized pathology slides (7+ million slides) from Memorial Sloan Kettering Cancer Center to develop FDA-cleared and CE-marked diagnostic tools for pathologists and oncologists.
Paige has been acquired
This company is no longer available on our private secondary market.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2018
Employees
100–200
Total Funding
$301.25M
6 rounds
Latest Valuation
$0.08B
August 22, 2025
Total raised $301.25M across 6 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Acquisition by Tempus
Date
August 22, 2025
Amount
$81.25M
Valuation
$0.08B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| August 22, 2025 | Acquisition by Tempus | $81.25M | $0.08B | Tempus AI |
| 2023 | Series C Extension | $25M | — | Not disclosed |
| January 14, 2021 | Series C | $100M | — | Casdin Capital, Johnson & Johnson Innovation |
Thomas Fuchs
Co-Founder, Chief Scientist
David Klimstra
Founder, Chief Medical Officer
Andy Moye
Chief Executive Officer
Jill Stefanelli
President, Chief Business Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
PathAI
AI-powered research tools and services for pathology, delivering diagnosis and treatment of cancer through machine learning approaches
Ibex
AI-based cancer diagnostics company providing diagnostic solutions for pathology that assist in detecting cancer and tissue features
Owkin
Develops AI-based decision-support tools for pathology, including microsatellite instability detection in colorectal cancer
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.